NCT01550341

HIV, Buprenorphine, and the Criminal Justice System

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Yale University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aims of STRIDE were changed as of July, 2014. The revised project, called STRIDE2, has a longitudinal, non-randomized, observational study design. The population under study consists of individuals living with HIV who are dependent on opioids.

Detailed description

Presented in the results section are the summary of outcomes from the STRIDE RCT that were collected prior to the change in study design. The STRIDE study became STRIDE2 (NCT03583138). Those individuals originally enrolled in the STRIDE RCT will be followed for 12 months. STRIDE2 will assist in identifying and monitoring individuals' HIV risk behaviors and provide resources to seek treatment for their HIV care and substance use. The goal of STRIDE2 is to examine if there are differences in HIV, drug use, and other outcomes between individuals receiving treatment versus individuals actively using, not actively using and not in treatment, and individuals on Methadone, Suboxone, or in some other treatment.

Conditions

• Human Immunodeficiency Virus
• Acquired Immunodeficiency Syndrome
• Opiate Addiction
• Drug Dependence

Interventions

Type	Name	Description
DRUG	Buprenorphine/naloxone	2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.
DRUG	Placebo Oral Tablet	2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.

Timeline

• Start date: 2012-02-23
• Primary completion: 2015-11-30
• Completion: 2016-11-30
• First posted: 2012-03-12
• Last updated: 2020-05-06
• Results posted: 2020-05-06

Locations

1 site across 1 country: United States